christof

[The ASCO Post @ASCOPost]

🆕 phase III data in cisplatin-ineligible #MIBC:
Perioperative enfortumab vedotin + pembrolizumab improved outcomes vs surgery alone.
📊 pCR: 57.1% vs 8.6%
📈 Improved EFS & OS
⚠️ More grade ≥3 AEs
🩺 Christof Vulsteke, MD, PhD (@cvulsteke) | @NEJM
🔗 https://t.co/Esmr1aDkAL

[The ASCO Post @ASCOPost]

🧬 Phase III KEYNOTE-905: In cisplatin-ineligible #MIBC, perioperative enfortumab vedotin + pembrolizumab improved outcomes vs surgery alone.
▫️ 2-yr EFS: 74.7% vs 39.4%
▫️ 2-yr OS: 79.7% vs 63.1%
👨‍⚕️ Christof Vulsteke, MD, PhD (@cvulsteke) | @NEJM
🔗 https://t.co/xRPHbLjBvU

[christof @cvulsteke]

@dr_yakupergun @visheshkhannaMD @OncBrothers 8.6%pCR in control indeed

[christof @cvulsteke]

A paradigm shift in bladder Cancer Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer | New England Journal of Medicine https://t.co/nn3afWv1Of @shilpaonc @y_loriot

[D Schampers @DSchampers]

Results from the phase 3 Keynote-905/EV-303 now available.

Congrats to the investigators.

@cvulsteke

#OncoAlert
#CTUIntegratedCancerCenterGhent

[christof @cvulsteke]

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer | New England Journal of Medicine
https://t.co/nn3afWv1Of

[NEJM @NEJM]

In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years. Full phase 3 KEYNOTE-905/EV-303 trial results: https://t.co/6M3xhml0ou

Editorial: Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy https://t.co/3uNr9TUukQ

[Tom Powles @tompowles1]

EV/Pembro has another positive trial (EFS & OS) in MIBC. This time vs chemo/surgery rather than just surgery (KN905 (pCR 57%)). Will these results be better than NIAGARA (chemo/durva OS-0.75). In M1 disease EVP>chemo/IO, but let’s see in MIBC. https://t.co/UEV0JiMz8a

[Uromigos @Uromigos]

🎯 the Eurasia team are now 6-0 ahead for the Uromigos cup 🏆 @MichvdHeijden is part of the team November 7th and 8th in Nashville. Here he is in beautiful Amsterdam among the canals 🇳🇱 🇳🇱 🇳🇱 🇳🇱 🇳🇱. Hearts ♥️ points. @OncoAlert

[Uromigos @Uromigos]

🚨 In this episode Christof Vulsteke joins Brian and Tom to discuss his practice-changing data on neoadjuvant EVP in MIBC. 

🎙️ GU Oncology Now:  https://t.co/tq6ij4QLoO 
 🍎 Apple Podcasts:  https://t.co/tq6ij4QLoO 
🎧Spotify:  https://t.co/Zm9En8bbMK

[Shilpa Gupta @shilpaonc]

#ESMO25 had 4 GU trials in the Presidential plenary sessions! @myESMO
On behalf our GU team, was proud to represent @CleClinicMD for 3/4! #IMvigor011, KN-905 and PSMAddition! Truly grateful to patients & families, my co- investigators & clinical research team for helping us make meaningful contributions to these practice changing trials!

@AmandaNizamMD @ChrisWeeMD @MosheOrnsteinMD @TimGilliganMD

[Tom Powles @tompowles1]

2/5 KN905 #ESMO25: Perioperative EVP in MIBC shows ⬆️ EFS,OS & pCR vs cystectomy alone in cisplatin ineligible MIBC. Gem/cis durvalumab showed pCR=37% & OS HR of 0.75. Will EVP be much better? Will it only apply to the cisplatin ineligible population? Will we see pembro only arm?

[Sumanta K. Pal, MD, FASCO @montypal]

Witnessed the incredible energy of the @myESMO Scientific Chairs this year. @DrChoueiri & @MyriamChalabi have put together a dazzling program. Check out the #ESMO25 Presidential Session titles 👇

[Shilpa Gupta @shilpaonc]

Congrats @DrChoueiri @MyriamChalabi on lining up such a fantastic @myESMO

Amazing to see 4 GU abstracts in the Presidential session!
Kudos to the GU scientific committee chair @montypal

@neerajaiims @PGrivasMDPhD @tompowles1 @Uromigos